Key Highlights

  • Frazier Life Sciences Acquisition II closed its IPO of 7,500,000 Class A shares at $10.00 each on October 15, 2026.
  • The company placed $75 million, or $10.00 per public share, in trust and has 24 months to complete a deal.
  • The sponsor bought $3 million of private placement shares, and an affiliated fund committed to buy at least $25 million.
  • The company has not selected a target and intends to focus on biotechnology, including oncology, autoimmune, cardiovascular and rare diseases.

Frazier Life Sciences Acquisition II (NASDAQ:FLSC) shares were trading near their 52-week high at USD 10.33 on October 19, 2026, down 0.19%. The Class A ordinary shares began trading on the Nasdaq Capital Market on October 14, 2026, a day after the registration statement was declared effective, and the $75 million offering closed on October 15. The Cayman Islands blank check company was incorporated on August 7, 2026, and says it has not selected a target.

A shares-only offering with no warrants

Frazier Life Sciences Acquisition II sold 7,500,000 Class A ordinary shares at $10.00 each, for gross proceeds of $75 million. Investors received shares only, with no warrants. The underwriting discount is $0.60 per share, of which $3.0 million in total is deferred.

The sponsor, Frazier Life Sciences Holdings II, LLC, an affiliate of Frazier Life Sciences Management, L.P., bought 300,000 private placement shares at $10.00 each for $3 million. Those shares are subject to a transfer restriction until 30 days after an initial business combination. The initial shareholders also hold 1,875,000 Class B ordinary shares, for which the sponsor paid $25,000, after 281,250 founder shares were forfeited in September 2026. In total they own 2,175,000 shares, or 22.5% of those outstanding after the offering and private placement.

Trust account, redemption rights and the 24-month clock

At closing, $75 million, equal to $10.00 per public share, went into a U.S. trust account with Continental Stock Transfer & Trust Company as trustee. Public shareholders may redeem their shares for a pro rata portion of the trust balance, net of taxes paid or payable, when a business combination is completed. A holder is restricted from redeeming more than an aggregate 15% of the public shares without the company's consent.

The company has 24 months from the closing of the offering to complete an initial business combination. It may seek shareholder approval to extend that period, but says it does not expect to go beyond 36 months, in line with Nasdaq Rule IM 5101-2. If no deal is completed in time, the public shares will be redeemed.

Forward purchase, dilution and disclosed risks

Frazier Life Sciences Public Fund, L.P. has committed to buy at least 2,500,000 Class A ordinary shares at $10.00 each, a minimum of $25 million, in a transaction closing alongside the initial business combination. The commitment is subject to approval by the fund's investment committee before the company signs a definitive agreement.

The prospectus flags several risks. The nominal price paid for the founder shares and their ownership by affiliates and directors create conflicts of interest. The ability of public shareholders to redeem a large number of shares is listed as a risk, as is the possible issuance of additional Class A ordinary shares to complete a deal, which could dilute holders. The company is an emerging growth company and a smaller reporting company.

What the documents say comes next

The company intends to look for opportunities in biotechnology, including therapeutics in oncology, autoimmune disease, cardiovascular disease and rare diseases, though it may pursue a business in any industry, sector or location. Albert Cha, M.D., Ph.D., a managing partner at Frazier Life Sciences Management, serves as chief executive officer, and Benjamin Palleiko is chairman.

The prospectus notes that an earlier blank check company, Frazier Lifesciences Acquisition Corporation, completed its initial business combination with NewAmsterdam Pharma Holding B.V. on November 22, 2022. For the new company, no target has been named and no one acting on its behalf has held substantive discussions with one. Any deal remains subject to Nasdaq shareholder approval rules while the shares stay listed there.